YOLFTbeta
Can Fite Biopharma Ltd ADR

Can Fite Biopharma Ltd ADR

CANF · AMEX · Healthcare / Biotechnology

1.42USD-0.07 (-4.70%)

Price History

Full chart

Market Stats

Previous Close1.49
Open1.48
Day Range1.42 – 1.52
52-Week Range2.15 – 12.80
Volume17.32K
Market Cap4.63M
P/E (TTM)0.00
Forward P/E2.97
EPS-4.65
Dividend Yield0.00%
Beta-0.04
50-Day Avg2.98
200-Day Avg3.58

About

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, It offers cannabinoids for treatment of conditions associated with elevated expression of the A3 adenosine receptors. Further, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Motti Farbstein
  • Employees5
  • Headquarters26 Ben Gurion Street, Ramat Gan, Israel, 5257346, USA
  • Websitehttps://www.canfite.com

Leadership

  • Dr. Pnina Fishman Ph.D.Founder, Chief Scientific Officer & Executive Chairperson · b. 1948
  • Mr. Motti FarbsteinCEO, CFO, Financial & Operating Officer · b. 1964
  • Dr. Sari Fishman Ph.D.Vice President of Business Development · b. 1972
  • Dr. Stephen A. Harrison FACP, M.D.Member of Clinical Advisory Board & Consulting Chief Medical Officer

Financials

Income Statement

Currency: USD2010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue745.21K469.00K-1.78M0164.72K169.50K844.75K3.82M2.03M763.00K853.00K810.00K743.00K674.00K408.21K
Growth (%)--37.07%---100.00%-+2.90%+398.38%+352.21%-46.81%-62.45%+11.80%-5.04%-8.27%-9.29%-39.43%
Cost of Revenue-5.21M-00-282.79-499.66-2.25K87.00K51.00K---15.00K7.03K24.19K
Gross Profit745.21K469.00K-1.78M0164.72K169.50K844.75K3.82M2.03M763.00K853.00K810.00K743.00K674.00K384.02K
Gross Margin100.00%100.00%-100.00%-100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%94.07%
Operating Expense4.51M5.24M-10.78M7.13M6.58M8.80M8.22M9.23M14.04M14.90M13.70M10.91M8.94M8.80M10.41M
Operating Income-3.76M-4.78M-5.99M-8.99M-7.13M-6.42M-8.63M-7.38M-5.41M-12.01M-14.14M-12.84M-10.10M-8.20M-8.13M-10.03M
Operating Margin-505.07%-1018.32%--503.71%--3894.56%-5093.72%-873.13%-141.73%-590.90%-1853.08%-1505.51%-1246.42%-1102.96%-1206.23%-2456.80%
EBITDA-3.53M-7.33M-5.98M-9.01M-7.12M-6.40M-8.68M-7.17M-6.13M-11.99M-14.13M-12.83M-10.08M-8.18M-8.12M-10.00M
EBITDA Margin-473.07%-1563.53%--504.94%--3884.61%-5119.17%-848.30%-160.37%-590.21%-1851.51%-1503.87%-1244.69%-1100.94%-1205.19%-2450.87%
Net Income-3.68M-6.70M-5.57M-8.34M-6.10M-4.80M-6.90M-4.97M-6.57M-12.63M-14.44M-12.60M-10.24M-7.63M-7.88M-9.91M
Net Income Margin-493.50%-1428.52%--467.31%--2912.29%-4069.33%-588.18%-172.02%-621.31%-1892.92%-1476.55%-1263.70%-1027.46%-1169.14%-2426.67%
R&D2.82M3.41M3.52M4.42M4.16M3.86M6.08M5.27M6.08M10.98M11.95M9.85M7.76M5.98M5.76M6.75M
R&D as % of Total Revenue377.95%726.56%-247.58%-2340.90%3585.90%624.05%159.03%540.16%1566.32%1154.75%958.40%805.25%854.15%1652.60%
Interest Expense7.33K377.56K7.23K16.08K14.89K564.34K27.30K1.10M1.20M427.00K363.00K227.00K63.00K14.00K14.00K14.11K
Interest Expense % of Total Revenue0.98%80.50%-0.90%-342.61%16.10%130.18%31.52%21.01%47.58%26.61%7.78%1.88%2.08%3.46%

Balance Sheet

Currency: USD2010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets-4.90M1.64M6.63M10.19M17.60M10.17M7.83M7.95M8.17M9.52M20.25M9.28M9.99M9.12M9.51M
Total Liabilities-1.61M2.34M2.18M3.33M7.16M6.29M4.78M4.94M5.73M3.45M5.87M4.81M3.75M3.68M3.92M
Total Equity-2.71M-1.24M3.80M6.48M10.32M3.87M3.05M3.02M2.44M6.07M14.38M4.47M6.24M5.44M5.59M
Cash-3.84M1.15M5.96M9.27M16.91M8.11M3.50M3.62M2.70M8.27M4.39M2.98M4.28M4.83M5.53M
Total Debt---------75.00K67.00K124.00K62.00K40.00K104.00K71.00K
Net Debt--3.84M-1.15M-5.96M-9.27M-16.91M-8.11M-3.50M-3.62M-2.62M-8.20M-4.27M-2.92M-4.24M-4.72M-5.46M

Cash Flow

Currency: USD2010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-3.65M-5.50M-4.35M-8.63M-7.33M-4.65M-8.93M-9.52M-4.16M-10.83M-12.06M-9.86M-10.80M-8.44M-7.64M-9.02M
Investing Cash Flow-30.16K21.54K20.07K-10.34K-9.50K-42.78K-10.40K-29.64K-33.00K-253.00K-26.00K-14.51M9.50M498.00K1.50M-2.02K
Financing Cash Flow3.38M4.64M1.50M13.22M11.47M12.38M04.88M4.39M10.17M17.68M20.46M20.46M9.14M6.71M9.72M
Capital Expenditure30.16K21.28K4.55K12.35K9.50K45.34K10.40K6.91K33.00K3.00K26.00K11.00K9.00K2.00K5.00K2.02K
Free Cash Flow-3.68M-5.52M-4.35M-8.64M-7.34M-4.70M-8.94M-9.53M-4.19M-10.84M-12.09M-9.87M-10.81M-8.44M-7.64M-9.02M
Dividends Paid-----------715.00K2.59M---
FCF to OCF100.83%100.39%100.10%100.14%100.13%100.97%100.12%100.07%100.79%100.03%100.22%100.11%100.08%100.02%100.07%100.02%
Dividend Paid to FCF------------7.24%-23.96%---

Earnings

Report DateDec 31, 2012May 29, 2013Aug 28, 2013Nov 29, 2013Mar 30, 2014May 29, 2014Sep 2, 2014Dec 1, 2014Mar 27, 2015May 29, 2015Aug 27, 2015Nov 27, 2015Mar 31, 2016May 27, 2016Aug 26, 2016Nov 25, 2016Mar 31, 2017May 30, 2017Sep 1, 2017Nov 27, 2017Mar 23, 2018Jun 1, 2018Aug 31, 2018Nov 26, 2018Jan 17, 2019May 29, 2019Aug 29, 2019Nov 29, 2019Mar 27, 2020Jun 1, 2020Aug 27, 2020Nov 30, 2020Mar 25, 2021May 27, 2021Aug 26, 2021Nov 26, 2021Mar 24, 2022May 26, 2022Aug 25, 2022Nov 25, 2022Mar 23, 2023Jun 1, 2023Aug 31, 2023Nov 30, 2023Mar 28, 2024Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Apr 14, 2025Aug 28, 2025Sep 30, 2025Dec 31, 2025
EPS Estimate----42.00-31.50-690.00-1080.00-510.00-11.12-300.00-255.00-150.00-1.50-270.00-420.00-195.00-10.50-270.00-270.00-360.00-9.00-240.00-0.06-0.06-0.07-390.00-330.00-156.00-0.89-118.00-72.00-48.00-2.10-38.00-10.67-0.90-1.80-28.00-17.00-21.00-0.09-38.00-14.50-8.60-7.40-0.52-0.22-0.24-0.25-0.41-2.40-2.80-2.80
EPS Actual-929.10-848.53-656.5030.00-66.00-330.00-300.00-150.00-27.00-60.00-210.00-450.000.45-180.00-120.00-270.00-1.05-120.00-180.00-120.00-10.50-300.00-180.00-0.13-2.78-240.00-240.00-180.00-0.44-180.00-60.00-47.78-3.00-1.20-60.00-60.00-3.00-0.90-0.80-60.00-1.11-0.65-0.42-0.44-60.00----0.000.00--
Surprise---171.43%-109.52%52.17%72.22%70.59%-142.81%80.00%17.65%-200.00%130.00%33.33%71.43%-38.46%90.00%55.56%33.33%66.67%-16.67%-25.00%-299900.00%-124.00%-3871.43%38.46%27.27%-15.38%51.07%-52.54%16.67%0.46%-42.86%96.84%-462.32%-6566.67%-66.67%96.79%95.29%-185.71%-1180.62%98.29%97.10%94.88%-710.81%----100.00%100.00%--
Timing-----Pre-marketPre-marketPre-marketAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-After-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-marketPre-marketPre-market-----Pre-market--

Key Statistics & Ratios

Market Cap4.63M
Enterprise Value-2.24M
Trailing P/E0.00
Forward P/E2.97
PEG Ratio0.00
Price / Sales11.44
Price / Book0.95
EPS-4.65
Book Value2.27
Revenue (TTM)405.00K
Gross Profit (TTM)405.00K
EBITDA-9.73M
Profit Margin0.00%
Operating Margin-2316.83%
Return on Equity-211.37%
Return on Assets-77.12%
Shares Outstanding2.14M
Shares Float2.14M
Beta-0.04
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 2 analystsTarget 8.00
  • Strong Buy
    2

Dividends

20131×
0.17Nov 12, 2013

Stock Splits

  • Jan 5, 20261:20
  • Jan 9, 20231:10
  • May 10, 20191:15